Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute ischemic stroke (scoring 3-20 on the National Institutes of Health Stroke Scale \[NIHSS\]) with level of consciousness score: 0 or 1 (conscious patients) are eligible to be treated within 9 hours of onset of stroke symptoms.~* For female patients: post-menopausal or surgically sterile (post-menopausal: age ≥55 years and last menses ≥3 years ago).~Exclusion Criteria:~* Participation in any investigational study in the previous 30 days.~* Patients unable to understand trial related information.~* History or evidence of severe heart diseases further specified in the protocol.~* History or evidence of additional diseases or results of baseline visit as specified in the protocol.~* Use of concomitant and prior medications as defined in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Enecadin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).